Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4834-4844

  Cho, Er Chieh ^a   Kuo, Mei Ling ^b   Liu, Xiyong ^b   Yang, Lixin ^b   Hsieh, Yi Chen ^a   Wang, Jinghan ^c   Cheng, Yawen ^a   Yen, Yun ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Biomarker; Cancer; RRM2B; Tumor suppressor FOXO3

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2B; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN P53; RRM2B PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUNG CANCER; METASTASIS; PLASMID; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TISSUE MICROARRAY; WESTERN BLOTTING; BINDING SITE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

BINDING SITES; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASES; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84905001944     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2044     Document Type: Article

References (45)

1. Cerqueira NM, Fernandes PA and Ramos MJ. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov. 2007; 2(1):11-29.
2. Shao J, Zhou B, Chu B and Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets. 2006; 6(5):409-431.
3. Liu X, Lai L, Wang X, Xue L, Leora S, Wu J, Hu S, Zhang K, Kuo ML, Zhou L, Zhang H, Wang Y, Wang Y, Zhou B, Nelson RA, Zheng S, et al. Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer research. 2011; 71(9):3202-3213.
4. Liu X, Xue L and Yen Y. Redox property of ribonucleotide reductase small subunit M2 and p53R2. Methods Mol Biol. 2008; 477:195-206.
5. Chang L, Zhou B, Hu S, Guo R, Liu X, Jones SN and Yen Y. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(47):18519-18524.
6. Liu X, Zhou B, Xue L, Yen F, Chu P, Un F and Yen Y. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 2007; 6(5):374-381.
7. Xue L, Zhou B, Liu X, Wang T, Shih J, Qi C, Heung Y and Yen Y. Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer research. 2006; 66(4):1900-1905.
8. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F and Yen Y. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer research. 2003; 63(20):6583-6594.
9. Xie M, Yen Y, Owonikoko TK, Ramalingam SS, Khuri FR, Curran WJ, Doetsch PW and Deng X. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase. Cancer research. 2014; 74(1):212-223.
10. Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, Qi C, Chu P, Un F, Wen W and Yen Y. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res. 2006; 12(21):6337-6344.
11. Xue L, Zhou B, Liu X, Qiu W, Jin Z and Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer research. 2003; 63(5):980-986.
12. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000; 404(6773):42-49.
13. Nakano K, Balint E, Ashcroft M and Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene. 2000; 19(37):4283-4289.
14. Hakansson P, Hofer A and Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem. 2006; 281(12):7834-7841.
15. Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, Chretien D, de Lonlay P, Paquis-Flucklinger V, Arakawa H, Nakamura Y, Munnich A and Rotig A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nature genetics. 2007; 39(6):776-780.
16. Xue L, Zhou B, Liu X, Heung Y, Chau J, Chu E, Li S, Jiang C, Un F and Yen Y. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer research. 2007; 67(1):16-21.
17. Zhang K, Wu J, Wu X, Wang X, Wang Y, Zhou N, Kuo ML, Liu X, Zhou B, Chang L, Ann D and Yen Y. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Molecular cancer therapeutics. 2011; 10(2):269-278.
18. Piao C, Jin M, Kim HB, Lee SM, Amatya PN, Hyun JW, Chang IY and You HJ. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene. 2009; 28(21):2173-2184.
19. Kuo ML, Sy AJ, Xue L, Chi M, Lee MT, Yen T, Chiang MI, Chang L, Chu P and Yen Y. RRM2B suppresses activation of the oxidative stress pathway and is up-regulated by p53 during senescence. Sci Rep. 2012; 2:822.
20. Wang X, Liu X, Xue L, Zhang K, Kuo ML, Hu S, Zhou B, Ann D, Zhang S and Yen Y. Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells. Biochem Biophys Res Commun. 2011; 410(1):102-107.
21. Kang MY, Kim HB, Piao C, Lee KH, Hyun JW, Chang IY and You HJ. The critical role of catalase in prooxidant and antioxidant function of p53. Cell Death Differ. 2013; 20(1):117-129.
22. Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lin CH, Lee H and Cheng YW. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer research. 2011; 31(10):3475-3481.
23. Yanamoto S, Kawasaki G, Yoshitomi I and Mizuno A. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer letters. 2003; 190(2):233-243.
24. Lehmann BD and Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol. 2012; 30(29):3648-3650.
25. Joerger AC and Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010; 2(6):a000919.
26. Garritano S, Inga A, Gemignani F and Landi S. More targets, more pathways and more clues for mutant p53. Oncogenesis. 2013; 2:e54.
27. Muller PA and Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013; 15(1):2-8.
28. Chang L, Guo R, Huang Q and Yen Y. Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms. Cell Rep. 2013; 3(5):1389-1397.
29. Zhang Y, Gan B, Liu D and Paik JH. FoxO family members in cancer. Cancer biology & therapy. 2011; 12(4):253-259.
30. Tzivion G, Dobson M and Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 2011; 1813(11):1938-1945.
31. Carbajo-Pescador S, Mauriz JL, Garcia-Palomo A and Gonzalez-Gallego J. FoxO Proteins: Regulation and Molecular Targets in Liver Cancer. Curr Med Chem. 2014; 21(10):1231-1246.
32. van der Vos KE and Coffer PJ. The extending network of FOXO transcriptional target genes. Antioxidants & redox signaling. 2011; 14(4):579-592.
33. Tseng AH, Shieh SS and Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med. 2013; 63:222-234.
34. Li G, Lee YF, Liu S, Cai Y, Xie S, Liu NC, Bao BY, Chen Z and Chang C. Oxidative stress stimulates testicular orphan receptor 4 through forkhead transcription factor forkhead box O3a. Endocrinology. 2008; 149(7):3490-3499.
35. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH and DePinho RA. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007; 128(2):309-323.
36. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA and Natarajan R. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol. 2006; 17(12):3325-3335.
37. Sandoval S, Kraus C, Cho EC, Cho M, Bies J, Manara E, Accordi B, Landaw EM, WolffL, Pigazzi M and Sakamoto KM. Sox4 cooperates with CREB in myeloid transformation. Blood. 2012; 120(1):155-165.
38. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet. 2003 Aug;34(4):440-5.
39. Kawakita K, Nishiyama T, Fujishiro T, Hayashi S, Kanzaki N, Hashimoto S, Takebe K, Iwasa K, Sakata S, Nishida K, Kuroda R and Kurosaka M. Akt phosphorylation in human chondrocytes is regulated by p53R2 in response to mechanical stress. Osteoarthritis Cartilage. 2012; 20(12):1603-1609.
40. Levine AJ and Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-758.
41. Renault VM, Thekkat PU, Hoang KL, White JL, Brady CA, Kenzelmann Broz D, Venturelli OS, Johnson TM, Oskoui PR, Xuan Z, Santo EE, Zhang MQ, Vogel H, Attardi LD and Brunet A. The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor. Oncogene. 2011; 30(29):3207-3221.
42. You H and Mak TW. Crosstalk between p53 and FOXO transcription factors. Cell Cycle. 2005; 4(1):37-38.
43. You H, Yamamoto K and Mak TW. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(24):9051-9056.
44. Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, McGouran J, Coutts AS, Kessler B, Kerr DJ and Thangue NB. Arginine methylation controls growth regulation by E2F-1. EMBO J. 2012; 31(7):1785-1797.
45. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B and La Thangue NB. Arginine methylation regulates the p53 response. Nat Cell Biol. 2008; 10(12):1431-1439.